CASI Pharmaceuticals, Inc. (CASI)

Market Cap	35.38M
Revenue (ttm)	34.91M
Net Income (ttm)	-32.10M
Shares Out	13.61M
EPS (ttm)	-2.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jun 2, 2022

Volume	23,322
Open	2.66
Previous Close	2.89
Day's Range	2.60 - 2.79
52-Week Range	2.24 - 12.40
Beta	0.44
Analysts	Buy
Price Target	23.12 (+789.2%)
Earnings Date	Nov 10, 2022

About CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and...

• Industry: Biotechnology
• IPO Date: Jun 11, 1996
• CEO: Wei-Wu He
• Employees: 176
• Stock Exchange: NASDAQ
• Ticker Symbol: CASI

Full Company Profile

Financial Performance

In 2021, CASI's revenue was $30.17 million, an increase of 99.25% compared to the previous year's $15.14 million. Losses were -$36.65 million, -24.09% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CASI stock is "Buy." The 12-month stock price forecast is 23.12, which is an increase of 789.23% from the latest price.

Price Target

$23.12

(789.23% upside)

Analyst Consensus: Buy

Stock Forecasts